Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: What have we learned from GWASs?

Trends in Endocrinology and Metabolism

Volumn 26, Issue 4, 2015, Pages 176-184

  Hannou, Sarah Anissa ^a,b,c,d,e   Wouters, Kristiaan ^f   Paumelle, Réjane ^a,b,c,d   Staels, Bart ^a,b,c,d  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c France   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e Institut Pasteur de Lille   (France)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ANRIL; Cardiovascular disease; CDKN2A; CDKN2B; GWAS; Type 2 diabetes

Indexed keywords

CARDIOVASCULAR DISEASE; CDKN2A GENE; CDKN2B GENE; CELL FUNCTION; CHROMOSOME 9P; CHRONIC INFLAMMATION; DIABETES MELLITUS; EXPERIMENTAL MODEL; FUNCTIONAL GENOMICS; GENE; GENE EXPRESSION; GENE LOCUS; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; MACROPHAGE; METABOLIC DISORDER; METABOLISM; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK; VASCULAR REMODELING; ANIMAL; CHROMOSOME 9; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION; GENETICS; GENOMICS; KNOCKOUT MOUSE; MOUSE; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

CDKN2A PROTEIN, MOUSE; CDKN2B PROTEIN, HUMAN; CDKN2B PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 9; CORONARY ARTERY DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIABETES MELLITUS, TYPE 2; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MICE; MICE, KNOCKOUT; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84933679127     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.01.008     Document Type: Review

References (90)

1. Dauriz M., Meigs J.B. Current insights into the joint genetic basis of type 2 diabetes and coronary heart disease. Curr. Cardiovasc. Risk Rep. 2014, 8:1-12.
2. Helgadottir A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
3. Burton P.R., et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
4. McPherson R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
5. Roberts R., Stewart A.F.R. 9p21 and the genetic revolution for coronary artery disease. Clin. Chem. 2012, 58:104-112.
6. Hinohara K., et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J. Hum. Genet. 2008, 53:357-359.
7. Shen G-Q., et al. Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2008, 28:360-365.
8. Dandona S., et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J. Am. Coll. Cardiol. 2010, 56:479-486.
9. Helgadottir A., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 2008, 40:217-224.
10. Patel R.S., et al. Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2014, 63:2234-2245.
11. Congrains A., et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 2012, 220:449-455.
12. Foulkes W.D., et al. The CDKN2A (p16) gene and human cancer. Mol. Med. 1997, 3:5-20.
13. Sharpless N.E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 2005, 576:22-38.
14. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 2006, 7:667-677.
15. Holdt L.M., et al. Expression of Chr9p21 genes CDKN2B (p15INK4b), CDKN2A (p16INK4a, p14ARF) and MTAP in human atherosclerotic plaque. Atherosclerosis 2011, 214:264-270.
16. Jarinova O., et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1671-1677.
17. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
18. Zhang Y., et al. Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway. FASEB J. 2009, 23:1358-1365.
19. Liu Y., et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS ONE 2009, 4:e5027. 10.1371/journal.pone.0005027.
20. Folkersen L., et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS ONE 2009, 4:e7677. 10.1371/journal.pone.0007677.
21. Holdt L.M., et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler. Thromb. Vasc. Biol. 2010, 30:620-627.
22. Cunnington M.S., et al. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 2010, 6:e1000899. 10.1371/journal.pgen.1000899.
23. Almontashiri N.A.M., et al. Interferon-γ activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype. J. Am. Coll. Cardiol. 2013, 61:143-147.
24. Pilbrow A.P., et al. The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS ONE 2012, 7:e39574. 10.1371/journal.pone.0039574.
25. Motterle A., et al. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum. Mol. Genet. 2012, 21:4021-4029.
26. Almontashiri N.A., et al. Abstract 15730: serum interferon alpha 21 is a biomarker of the 9p21.3 risk locus for coronary artery disease. Circulation 2011, 124:A15730.
27. Congrains A., et al. ANRIL: molecular mechanisms and implications in human health. Int. J. Mol. Sci. 2013, 14:1278-1292.
28. Broadbent H.M., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum. Mol. Genet. 2008, 17:806-814.
29. Kotake Y., et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2011, 30:1956-1962.
30. Pasmant E., et al. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011, 25:444-448.
31. Harismendy O., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature 2011, 470:264-268.
32. Erridge C., et al. The 9p21 locus does not affect risk of coronary artery disease through induction of type 1 interferons. J. Am. Coll. Cardiol. 2013, 62:1376-1381.
33. Gschwendtner A., et al. Sequence variants on chromosome 9p21.3 confer risk of atherosclerotic stroke. Ann. Neurol. 2009, 65:531-539.
34. Minamino T., et al. Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation 2003, 108:2264-2269.
35. Kim J.B., et al. The effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice. Circulation 2012, 126:1896-1906.
36. Visel A., et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010, 464:409-412.
37. Kuo C-L., et al. Cdkn2a is an atherosclerosis modifier locus that regulates monocyte/macrophage proliferation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2483-2492.
38. Gizard F., et al. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J. Clin. Invest. 2005, 115:3228-3238.
39. González-Navarro H., et al. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J. Am. Coll. Cardiol. 2010, 55:2258-2268.
40. Leeper N.J., et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler. Thromb. Vasc. Biol. 2013, 33:e1-e10. 10.1161/ATVBAHA.112.300399.
41. Braun-Dullaeus R.C., et al. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998, 98:82-89.
42. Boesten L.S.M., et al. Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. FASEB J. 2006, 20:953-955.
43. Robbins C.S., et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 2013, 19:1166-1172.
44. Díez-Juan A., Andrés V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J. 2001, 15:1989-1995.
45. Díez-Juan A., et al. Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood 2004, 103:158-161.
46. Guevara N.V., et al. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 1999, 5:335-339.
47. Merched A.J., et al. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1608-1614.
48. Fuster J.J., et al. Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice. Atherosclerosis 2012, 221:98-105.
49. Cudejko C., et al. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 2011, 118:2556-2566.
50. Wouters K., et al. Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development. PLoS ONE 2012, 7:e32440. 10.1371/journal.pone.0032440.
51. Través P.G., et al. The tumor suppressor ARF regulates innate immune responses in mice. J. Immunol. 2011, 187:6527-6538.
52. Cardenas J.C., et al. Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:827-833.
53. Svensson P-A., et al. CDKN2B expression and subcutaneous adipose tissue expandability: possible influence of the 9p21 atherosclerosis locus. Biochem. Biophys. Res. Commun. 2014, 446:1126-1131.
54. Li H., et al. Association between type 2 diabetes and rs10811661 polymorphism upstream of CDKN2A/B: a meta-analysis. Acta Diabetol. 2013, 50:657-662.
55. Rees S.D., et al. Replication of 13 genome-wide association (GWA)-validated risk variants for type 2 diabetes in Pakistani populations. Diabetologia 2011, 54:1368-1374.
56. Scott L.J., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
57. Chauhan G., et al. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes 2010, 59:2068-2074.
58. Herminia González-Navarro A.V. Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging. Aging Cell 2012, 12:102-111.
59. Bianchi T., et al. The tumor suppressor p16Ink4a regulates T lymphocyte survival. Oncogene 2006, 25:4110-4115.
60. Erickson S., et al. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene 1998, 17:595-602.
61. Kim J-A., et al. The inhibition of T-cells proliferation by mouse mesenchymal stem cells through the induction of p16INK4A-cyclin D1/cdk4 and p21waf1, p27kip1-cyclin E/cdk2 pathways. Cell. Immunol. 2007, 245:16-23.
62. Bies J., et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood 2010, 116:979-987.
63. Zeyda M., et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int. J. Obes. (Lond.) 2007, 31:1420-1428.
64. Wentworth J.M., et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010, 59:1648-1656.
65. Fuentes L., et al. Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype. Diabetologia 2011, 54:3150-3156.
66. Huang Z.H., et al. PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity. J. Clin. Endocrinol. Metab. 2013, 98:E17-E24. 10.1210/jc.2012-2697.
67. Butler A.E., et al. Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52:2304-2314.
68. 't Hart L.M., et al. Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps. Diabetes 2010, 59:287-292.
69. Hribal M.L., et al. Glucose tolerance, insulin sensitivity and insulin release in European non-diabetic carriers of a polymorphism upstream of CDKN2A and CDKN2B. Diabetologia 2011, 54:795-802.
70. Köhler C.U., et al. Cell cycle control of beta-cell replication in the prenatal and postnatal human pancreas. Am. J. Physiol. Endocrinol. Metab. 2010, 300:E221-E230. 10.1152/ajpendo.00496.2010.
71. Moritani M., et al. Hypoplasia of endocrine and exocrine pancreas in homozygous transgenic TGF-beta1. Mol. Cell. Endocrinol. 2005, 229:175-184.
72. Krishnamurthy J., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
73. Krishnamurthy J., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 2004, 114:1299-1307.
74. Tschen S-I., et al. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes 2009, 58:1312-1320.
75. Dhawan S., et al. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev. 2009, 23:906-911.
76. Pascoe J., et al. Free fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 2012, 61:632-641.
77. Annicotte J-S., et al. The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat. Cell Biol. 2009, 11:1017-1023.
78. Rane S.G., et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat. Genet. 1999, 22:44-52.
79. Fajas L., et al. CDK4, pRB and E2F1: connected to insulin. Cell Div. 2010, 5:1-4.
80. Salas E., et al. Role of Ink4a/Arf locus in beta cell mass expansion under physiological and pathological conditions. J. Diabetes Res. 2014, Published online February 6, 2014. http://dx.doi.org/10.1155/2014/873679.
81. Fajas L., et al. E2Fs regulate adipocyte differentiation. Dev. Cell 2002, 3:39-49.
82. Bantubungi K., et al. Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway. Diabetes 2014, 63:3199-3209.
83. Lee Y., et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature 2014, 510:547-551.
84. Al-Khalaf H.H., et al. p16INK4A positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS ONE 2011, 6:e21111. 10.1371/journal.pone.0021111.
85. Cotsapas C., et al. Expression analysis of loci associated with type 2 diabetes in human tissues. Diabetologia 2010, 53:2334-2339.
86. Mody N., et al. Susceptibility to diet-induced obesity and glucose intolerance in the APP SWE/PSEN1 A246E mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 2011, 54:2143-2151.
87. Gu P., Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Rev. Endocr. Metab. Disord. 2013, 14:49-58.
88. Nagano T., et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. Nature 2013, 502:59-64.
89. Dryden N.H., et al. Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. Genome Res. 2014, 24:1854-1868.
90. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998, 1378:F115-F177.